Cathie Wood's Ark Genomics Revolution ETF (ARKG) includes notable biotech innovators expected to benefit from AI developments, although it has lagged in performance recently. Twist Biosciences specializes in synthesizing DNA using a silicon-based process, showcasing various potential applications, though it may not be immediately profitable. Natera, in contrast, is positioned to expand its product offerings in the detection and testing sphere. Both companies represent compelling opportunities within the genomic revolution, with distinct paths to growth.
Twist Biosciences is a biotech firm that synthesizes DNA using its proprietary silicon-based process. The sky seems to be the limit when it comes to the applications of such a technology.
Natera is ready to add to its stacked test product portfolio, indicating significant potential for growth in the genomic sector.
Collection
[
|
...
]